Eli Lilly raises revenue outlook as weight-loss drug demand grows
💊 Eli Lilly reported Q3 revenue of $24.4 billion, up 39% year over year. Mounjaro and Zepbound remained the main drivers, contributing nearly 66% of total sales.
📈 The company raised its 2026 revenue forecast to $91–92 billion from $85–87 billion. The $5.5 billion midpoint increase reflects expectations for continued volume growth.
⚖️ Global sales volume rose 53%, while realized prices fell 15%. Higher volume is offsetting pricing pressure and supporting revenue growth.
🧾 Adjusted earnings guidance edged lower due to acquired research charges. This decline should be viewed separately from underlying business growth.
🔎 The key issue is whether volume growth can keep offsetting lower prices. That balance will help determine how sustainable Lilly’s revenue momentum remains.
#EliLilly $LLYB
💊 Eli Lilly reported Q3 revenue of $24.4 billion, up 39% year over year. Mounjaro and Zepbound remained the main drivers, contributing nearly 66% of total sales.
📈 The company raised its 2026 revenue forecast to $91–92 billion from $85–87 billion. The $5.5 billion midpoint increase reflects expectations for continued volume growth.
⚖️ Global sales volume rose 53%, while realized prices fell 15%. Higher volume is offsetting pricing pressure and supporting revenue growth.
🧾 Adjusted earnings guidance edged lower due to acquired research charges. This decline should be viewed separately from underlying business growth.
🔎 The key issue is whether volume growth can keep offsetting lower prices. That balance will help determine how sustainable Lilly’s revenue momentum remains.
#EliLilly $LLYB
